PD-L1 POSITIVE
Clinical trials for PD-L1 POSITIVE explained in plain language.
Never miss a new study
Get alerted when new PD-L1 POSITIVE trials appear
Sign up with your email to follow new studies for PD-L1 POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets hard-to-treat breast cancer
Disease control Not yet recruitingThis study tests whether combining two drugs (Sacituzumab Tirumotecan and Toripalimab) can shrink or control advanced triple-negative breast cancer that has a specific protein (PD-L1). About 41 women with this type of breast cancer will receive the treatment. The goal is to see h…
Matched conditions: PD-L1 POSITIVE
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
New combo therapy targets tough breast cancer in phase 2 trial
Disease control Not yet recruitingThis study tests a combination of two drugs, Sac-TMT and Tagitanlimab, in people with a specific type of advanced breast cancer (PD-L1-positive triple negative breast cancer) that has been treated before. The goal is to see if the combination shrinks tumors or slows cancer growth…
Matched conditions: PD-L1 POSITIVE
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 15, 2026 11:57 UTC